Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm studyLijuan Deng, Jun Zhu, Zhiming Li et al.|Blood Advances|2023Cited by 30
CHRDL2 promotes cell proliferation by activating the YAP/TAZ signaling pathway in gastric cancerLingquan Wang, Zhentian Ni, Wei Xu et al.|Free Radical Biology and Medicine|2022Cited by 18
Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II StudyYuqin Song, Jun Zhu, Yongping Song et al.|Blood|2020Cited by 17
Cardiac right‐to‐left shunt subtypes in <scp>C</scp>hinese patients with cryptogenic strokes: a multicenter case−control studyWei Xu, Shan Gao, Yingqi Xing et al.|European Journal of Neurology|2014Cited by 11
EBV-Mir-BART5-5p targets p53 independent pathway in cytoplasm: Potential role in EBV lymphomagenesisWei‐Ting Wang, Wei Xu, Jing-Ran Guo et al.|Genes & Diseases|2022Cited by 7